TITLE

Why do we overtreat hypertension?

AUTHOR(S)
Spence, Des
PUB. DATE
September 2012
SOURCE
BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/15/2012, Vol. 345 Issue 7874, p49
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article describes the author's views on overtreatment of disorder like high blood pressure. He states that even after clear guidelines which recommend treating hypertension only after a risk assessment using the QRisk algorithm, many doctors are ignoring this advice and treat according to blood pressure readings. According to the author, doctors do not look at the risk, because it is simpler to intervene early and involve everyone rather than getting criticised later.
ACCESSION #
80330493

 

Related Articles

  • Age-Dependent Impact of Medication Underuse and Strategies for Improvement. Meid, Andreas D.; Haefeli, Walter E. // Gerontology;Aug2016, Vol. 62 Issue 5, p491 

    Background: Medication underuse is common in aging populations and, because of the growing risk for competing deaths, the benefit of preventive medicines gradually vanishes with advancing age, thus limiting their success.Objective: To estimate the optimum time of...

  • Little gain for drug treatment of mild hypertension.  // Practice Nurse;9/7/2012, Vol. 42 Issue 13, p10 

    The article discusses a study which found that drug treatment for patients with mildly raised blood pressure has no significant impact on preventing cardiovascular events.

  • High blood pressure can be a silent killer. Muniz, Aida // Caribbean Business;6/25/1998, Vol. 26 Issue 25, p36 

    Focuses on high blood pressure or hypertension as a possibly fatal disease. Difficulty in determining high blood pressure; Its common causes; Association of hypertension with cardiovascular disease; Recommendations to keep blood pressure under control. INSET: A blood pressure quiz.

  • Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: Results... Whelton, Paul K.; Kumanyika, Shiriki K. // American Journal of Clinical Nutrition;Feb97 Supplement, Vol. 65, p652S 

    Presents the results of the first phase of the Trials of Hypertension Prevention which examined the efficacy of nonpharmacologic interventions in adults with high-normal blood pressure. Overall design of the study; Adherence to the protocol; Changes in blood pressure and incidence of hypertension.

  • More Nuanced Guidelines for Lipid Lowering to Prevent CVD. SHAUGHNESSY, ALLEN F. // American Family Physician;1/1/2016, Vol. 93 Issue 1, p59 

    The article provides an answer to the question of how risk should be assessed and what should be done about elevated lipid levels for the primary and secondary prevention of cardiovascular disease (CVD).

  • The need for better evidence in treating heart disease. Goozner, Merrill // Modern Healthcare;11/16/2015, Vol. 45 Issue 46, p0028 

    This article discusses the release in November 2015 of research which raised serious questions about how the U.S spends about 200 billion dollars each year on cardiac care. Topics covered include the reputation of heart disease as America's number 1 killer, the findings of a study on the...

  • British and American prevention guidelines: different committees, same science, considerable agreement. Greenland, Philip // Heart;May2014, Vol. 100 Issue 9, p678 

    In this article, the author focuses on the new British and American guidelines for the prevention of cardiovascular disease (CVD), and mention risk factors. The author mentions a draft document for numerous data summaries on cardiovascular risk assessment and modification of blood lipids for the...

  • Low-dose ASA use for primary prevention of cardiovascular disease in patients without diabetes: When should you recommend it? A case-based approach. Grieve, Kyle // Canadian Pharmacists Journal;Nov/Dec2011, Vol. 144 Issue 6, p278 

    The article examines the overall benefit of the daily use of low-dose acetylsalicylic acid (ASA) for the primary prevention of cardiovascular disease in patient without diabetes. It notes that the cardiovascular benefits of low-dose ASA therapy in primary prevention must outweigh the increased...

  • 2016 - Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of age. Pagidipati, Neha J.; Granger, Christopher B. // ACP Journal Club;3/20/2017, Vol. 166 Issue 6, p1 

    Guideline scope This guideline focuses on the use of statins to prevent cardiovascular disease (CVD) events in adults ≥ 40 years of age without CVD (history or current signs or symptoms), low-density lipoprotein cholesterol level > 190 mg/dL (4.9 mmol/L), or familial hypercholesterolemia....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics